Silk Road Medical, Inc
SILK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.77 | -2.78 | 5.60 | 1.10 |
| FCF Yield | -7.04% | -1.99% | -2.96% | -2.07% |
| EV / EBITDA | -11.99 | -40.90 | -31.05 | -49.56 |
| Quality | ||||
| ROIC | -25.06% | -22.20% | -35.37% | -28.39% |
| Gross Margin | 71.75% | 72.68% | 74.92% | 71.70% |
| Cash Conversion Ratio | 0.57 | 0.59 | 0.78 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.41% | 22.60% | 17.00% | 29.60% |
| Free Cash Flow Growth | 10.82% | 13.98% | -1.82% | -42.35% |
| Safety | ||||
| Net Debt / EBITDA | -1.43 | -0.45 | 1.35 | 0.50 |
| Interest Coverage | -8.63 | -10.20 | -18.85 | -9.72 |
| Efficiency | ||||
| Inventory Turnover | 1.68 | 1.96 | 1.43 | 2.13 |
| Cash Conversion Cycle | 225.06 | 209.02 | 264.49 | 170.71 |